he American Association of Neurological Surgeons and Congress of Neurological Surgeons are urging Congress to restore Medicare hospital outpatient payment rates for Cobalt-60-based stereotactic radiosurgery to those in place prior to the enactment of the American Taxpayer Relief Act.
[More]
The U. S. Patent and Trademark Office recently issued a patent to the U. S. Department of Health and Human Services involving resiniferatoxin, or RTX, an experimental compound that represents a potential new class of drugs to alleviate the intractable pain that can occur in people with advanced cancer, severe arthritis, and other extremely chronic conditions.
[More]
Neuros Medical, Inc., a medical device company, was presented the 2012 Gold Electrode Award for Most Promising Startup at the Neurotech Leaders Forum conference in San Francisco. The award is given by Neurotech Reports, and highlights a company in the neuromodulation industry that holds the most promise.
[More]
AMERICAN SHARED HOSPITAL SERVICES, a leading provider of turnkey technology solutions for advanced radiosurgical and radiation therapy services, today shared a recent announcement from Mevion Medical Systems, Inc. regarding Mevion Medical Systems' receipt of FDA 510(k) clearance for its MEVION S250 Proton Therapy System.
[More]
Convergence Pharmaceuticals Limited, the company focused on the development of novel and high value analgesic medicines, today announced that the Phase II proof of concept study for CNV1014802 for the treatment of pain associated with trigeminal neuralgia (TN) has started.
[More]
AMERICAN SHARED HOSPITAL SERVICES, a leading provider of turnkey technology solutions for advanced radiosurgical and radiation therapy services, today announced financial results for the fourth quarter and 2011.
[More]
AMERICAN SHARED HOSPITAL SERVICES, a leading provider of turnkey technology solutions for advanced radiosurgical and radiation therapy services, today announced financial results for the third quarter and first nine months of 2011.
[More]
AMERICAN SHARED HOSPITAL SERVICES, a leading provider of turnkey technology solutions for advanced radiosurgical and radiation therapy services, said today that the recent announcement by the Centers for Medicare & Medicade Services (CMS) of a 15% increase in the payment rate of proton therapy for hospital based centers beginning in 2012 strengthens the economic case for the proton centers now under development by the Company.
[More]
Laser Med Center, which specializes in treating Trigeminal Neuralgia, has received an FDA approval for its revolutionary laser device. This is a non-invasive alternative to surgery, which treats pain through nerve tissue regeneration.
[More]
A potentially treatable blood vessel abnormality in the brain may be the cause of Parkinson's Disease in some patients, according to a study published today in the journal Neurology International by a team of leading physicians and neuroscientists at Pittsburgh's Allegheny General Hospital.
[More]
AMERICAN SHARED HOSPITAL SERVICES, a leading provider of turnkey technology solutions for advanced radiosurgical and radiation therapy services, today announced financial results for the second quarter and first half of 2011.
[More]
In the labs of University of California, San Francisco and from the wilds of Venezuela scientists have discovered how vampire bats have evolved over the years with a unique weapon that enables them to zero in for a ravenous feed on the warmest blood vessels of their prey.
[More]
AMERICAN SHARED HOSPITAL SERVICES, a leading provider of turnkey technology solutions for advanced radiosurgical and radiation therapy services, announced today that it has entered into a contract to supply a Gamma Knife® Perfexion™ system to Lovelace Medical Center in Albuquerque, New Mexico.
[More]
How do certain multiple myeloma treatment drugs cause complications? How does the immune system become dysfunctional due to cancer? How safe is a vaccine that could prevent development of precancerous colon polyps? Those are among the many questions that will be answered by researchers from the University of Pittsburgh Cancer Institute and the University of Pittsburgh School of Medicine during the American Association for Cancer Research 102nd Annual Meeting 2011, April 2 to 6, in Orlando, Fla.
[More]
Neuros Medical, Inc., a medical device company, announced promising results today from their recently completed feasibility study. The study was the first human test of the Company's patented high frequency Electrical Nerve Block™ technology and focused on patients with chronic amputation pain which affects nearly one million patients in the U.S. During the study, four of the five patients reported their pain was reduced to zero.
[More]
Avanir Pharmaceuticals, Inc. today announced that it has filed an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) to begin a large Phase II clinical trial of AVP-923, an investigational drug for the treatment of central neuropathic pain in patients with multiple sclerosis (MS). The FDA has acknowledged receipt of the submission and the company expects that the IND filing will be subject to standard 30-day review.
[More]
Research published this week in the New England Journal of Medicine. A multinational team of scientists led by the Royal College of Surgeons in Ireland and the University of Liverpool has identified a gene that could indicate if epilepsy patients starting a common drug treatment are likely to experience side-effects ranging from a mild skin irritation to the potentially fatal Steven-Johnson Syndrome.
[More]
Internationally renowned brain surgeon Hrayr Shahinian, M.D., a pioneer in minimally invasive brain surgery, has announced that he is teaming with scientists and technologists at NASA's Jet Propulsion Laboratory in Pasadena, Calif., to design the next generation of high-tech surgical instruments - technology that also will be useful for planetary exploration.
[More]
Neuros Medical, Inc., a medical device company announced today initial feasibility study results of their patented high frequency alternating current (HFAC) Nerve Block technology from their first patient. The study is a short-term, 30-day test per patient, focusing on chronic residual limb pain. Nearly one million patients suffer from chronic residual limb pain in the U.S.
[More]
Pharmigene, a leader in advancing personalized medicine and reducing severe adverse reactions to drugs through genetic-based diagnostic solutions, today announced it has been granted patents in the United States, Europe, Australia, Singapore and Taiwan. The patents cover methods to detect the presence of key genetic alleles in individual patients being considered for treatment with drugs that have been linked to the development of adverse drug reactions including Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis.
[More]